Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
Revolution Medicines, Inc.
Leiden University Medical Center
Massachusetts General Hospital
Delfi Diagnostics Inc.
Medipol University
Navigation Sciences, Inc.
Philips Respironics
Hoffmann-La Roche
University of Alabama at Birmingham
Revolution Medicines, Inc.
Stanford University
University of Washington
VA Office of Research and Development
McGill University Health Centre/Research Institute of the McGill University Health Centre
Milton S. Hershey Medical Center
University Hospital Augsburg
Revolution Medicines, Inc.
University of Alberta
Erasme University Hospital
Checkpoint Therapeutics, Inc.
Syndax Pharmaceuticals
Syndax Pharmaceuticals
Syndax Pharmaceuticals
H. Lee Moffitt Cancer Center and Research Institute
University of Cologne
Mereo BioPharma
Hallym University Kangnam Sacred Heart Hospital
Jiangsu HengRui Medicine Co., Ltd.
University Health Network, Toronto
Shanghai Pulmonary Hospital, Shanghai, China
National Institutes of Health Clinical Center (CC)
VA Office of Research and Development
Royal Brompton & Harefield NHS Foundation Trust
New Mexico Cancer Research Alliance
AVEO Pharmaceuticals, Inc.
Sanofi
Nycomed
University of New Mexico
University Hospital, Bordeaux
Apeiron Biologics
National Institute of Environmental Health Sciences (NIEHS)